The specter of generic rivalry has long loomed above copyright’s iconic drug, PDE5 Inhibitor, triggering questions about the future of similar medicinal portfolios. While first years saw significant gains, the intellectual property expiration has allowed the Adult door for cheaper alternatives, potentially diminishing earnings and posing a signif